Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Hosted on MSN16h
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations SignificantlyBiotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
16don MSN
RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...
Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results